Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to

Status Completed

Clinical Trial Summary

Background: Infiltration of GI by T lymphocytes is a pathogenic mechanism both in ulcerative colitis (UC) and in Crohn's disease (CD). Vedolizumab (VDZ) is a humanized monoclonal antibody binding with high affinity to α4β7 integrin blocking α4β7+-MAdCAM-1 interaction, hence blocking a key step in GI lymphocytes T infiltration. VDZ has demonstrated a therapeutic effect in UC and CD. Investigators still lack of adequate biomarkers to predict clinical response to biological treatments, specially avoiding invasive procedures.

Objective: Study whether circulating CD4+ and CD8+ α4β7+ memory T lymphocytes and some of their surface markers might be molecular markers of response to VDZ treatment in patients with UC and CD.

Methods: Prospective (pilot) study including 24 adult IBD patients (12 UC patients and 12 CD patients (patients with fistulizing perianal disease will be excluded) with active disease and prior failure to anti-TNFα treatments starting treatment with VDZ. They will received VDZ in standard induction (300mg intravenously, 0-2-6 weeks) and maintenance schemes (300mg intravenously, every 8 weeks).

Epidemiological and clinical data from every patient will be recorded prospectively. Disease activity at weeks 0, 2, 6 and 14 weeks will be evaluated through validated clinical scores, biological parameters and fecal biomarkers.

At week 14 response to the treatment will be evaluated by ileocolonoscopy or enteroMRI.

Peripheral blood will be obtained from every patient at baseline, before the third infusion of VDZ (6th week) and before the first maintenance dose (14th week).

Blood lymphocytes will be isolated and multicolor flow cytometry will be performed on stored circulating memory T cells.

Percentage and absolute values of circulating CD4+ and CD8+ α4β7+ memory T lymphocytes as well as several surface markers related to their activation state (HLA-DR, CD25), Th17 phenotype (IL23R, CCR6, intracellular IL17A) and Th1 phenotype (INFγ)will be assessed on α4β7+ memory T cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02712866
Study type	Observational
Source	Parc de Salut Mar
Contact
Status	Completed
Phase
Start date	January 2017
Completion date	February 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03278912` - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Terminated	`NCT00061282` - Clotrimazole Enemas for Pouchitis in Children and Adults	Phase 1/Phase 2
Recruiting	`NCT05579392` - A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis	N/A
Completed	`NCT03264690` - Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
Recruiting	`NCT02861053` - Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?	N/A
Recruiting	`NCT02275676` - Resting Energy Expenditure and Nutritional Status in IBD	N/A
Completed	`NCT02197780` - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD	N/A
Completed	`NCT02503696` - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)	N/A
Completed	`NCT02161640` - Vascular Dysfunction in Paediatric IBD	N/A
Completed	`NCT01860651` - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease	N/A
Completed	`NCT01852760` - Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound	N/A
Completed	`NCT01933867` - Water-aided Colonoscopy in Inflammatory Bowel Disease Patients	N/A
Completed	`NCT01692743` - Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)	Phase 3
Completed	`NCT01688557` - Trial on Innovative Technologies in Colonoscopy	N/A
Completed	`NCT01666535` - Infliximab IBD Influenza Vaccine Study	N/A
Completed	`NCT01676324` - FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)	N/A
Completed	`NCT01557387` - Real-time Diagnosis of Pseudopolyps During Colonoscopy
Completed	`NCT01981616` - Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab	Phase 1
Completed	`NCT01221818` - A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects	Phase 1
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms